Campaigners for and against assisted dying make feelings known at Westminster
Dame Prue Leith, Dame Esther Rantzen's daughter, Rebecca Wilcox, and the broadcaster, Jonathan Dimbleby, were among the high-profile figures supporting the Bill to change the law in England and Wales.
Members of the Dignity in Dying campaign wore pink and held placards in memory of friends and family members.
Those opposed to the Bill included groups dressed as scientists in white lab coats and bloodied gloves and masks, as well as nuns and other members of religious organisations.
The mood amongst campaigners was largely calm and respectful on both sides.
Dame Prue told the PA news agency she was 'both nervous and confident' about the outcome.
'It's so moving to see all these people with placards of people they've lost or people who are dying of cancer,' she said.
'It's hard not to cry because I think they have done such a good job. Let's hope we've won.'
Mr Dimbleby said he believed the Bill would be 'transformative'.
He added: 'What it will mean is millions of people will be able to say to themselves, 'If I'm terminally ill, I will be able to choose, assuming I am of sound mind and I am not being coerced, to say 'Yes, I want to be assisted – I have dignity in death'.'
Rebecca Wilcox, the daughter of Dame Esther, said: 'It couldn't be a kinder, more compassionate Bill that respects choice at the end of life, that respects kindness and empathy and gives us all an option when other options, every other option, has been taken away, and it would just be the perfect tool for a palliative care doctor to have in their med bag.'
Teachers Catie and Becky Fenner said they wanted other families to benefit from the Bill.
Their mother, who had motor neurone disease, had flown to Dignitas in Switzerland to end her life at a cost of £15,000. The sisters said they did not get to properly say goodbye and grieve and worried about the legal repercussions.
Catie, 37, said: 'We were left quite traumatised by the whole experience – not only seeing a parent go through a really horrible disease but then the secrecy of the planning.'
Campaigners against the Bill, who were gathered outside Parliament, chanted 'We are not dead yet' and 'Kill the Bill, not the ill'.
A display was erected with a gravestone reading 'RIP: The Terminally Ill Adults (End of Life) Bill. Bury it deep', and behind were two mounds meant to resemble graves.
Andrew Hilliard, 75, said he was opposed for religious reasons. He was dressed in a white lab coat with a placard reading: 'Protect our NHS from becoming the National Suicide Service'.
The chief executive of Care Not Killing, Dr Gordon Macdonald, said MPs should prioritise improving palliative care.
He said: 'Most people, when thinking about the practical implications of this, for those most vulnerable, they change their minds.'
George Fielding, a campaigner affiliated with the Not Dead Yet group which is opposed to assisted dying, said he attended to represent disabled people.
He said: 'This Bill will endanger and shorten the lives of disabled people.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
39 minutes ago
- Daily Mail
Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL
A new fat-busting drug that is available as a jab or tablet helps patients lose up to a quarter of their body weight, studies suggest. People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of treatment. And those taking daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks, the early stage trials found. Weight loss jabs have been hailed as transformative by NHS leaders. But tablets could be the next big breakthrough in the nation's fight against obesity as they are likely to appeal to a wider audience who are uncomfortable with injecting themselves. An estimated 1.5million Britons use weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out fat jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body—GLP-1 and the amylin receptor. In comparison to amycretin, trials pivotal to getting semaglutide—the ingredient behind Ozempic—approved, show it helped users shed up to 15 per cent of their body weight over 68 weeks. And studies have found rival jab Mounjaro can help obese people lose up to 22.5 per cent of their body weight in 72 weeks. The new amycretin trial involved 125 adults, who took weekly injections of the drug. Those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment, according to findings published in medical journal The Lancet. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks. GLP-1 injections suffered global shortages after celebrity users sparked a surge in popularity and the NHS has warned people against buying them from unauthorised sources. Professor Sir Stephen Powis, national medical director at NHS England, last week told the NHS ConfedExpo conference in Manchester that weight loss jabs could be doled out as widely as statins if competition in the market brings their price down The country's top doctor warned obesity costs the NHS £11.4billion every year and described the financial burden as 'unsustainable'. From Monday, GPs will be able to prescribe the fat jab mounjaro - also known as tirzepatide - for the first time, in what he labelled an 'exciting milestone'.
The Independent
42 minutes ago
- The Independent
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association 's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
Daily Mail
an hour ago
- Daily Mail
Every newborn baby in the UK will have DNA screening in NHS 'revolution' to battle killer diseases, Wes Streeting reveals
Every newborn baby in the UK will have a DNA screening as part of an NHS 'revolution' to battle killer diseases. The health secretary Wes Streeting said new technology in areas such as genomics would help 'leapfrog' illnesses. The Government is set to pour £650 million into DNA technology in an effort to treat serious illnesses before they become a problem. The investment in genomics is expected to support the Government's 10-year plan for the NHS, which will see a greater focus on technology and prevention. Mr Streeting told The Telegraph: 'The revolution in medical science means that we can transform the NHS over the coming decade, from a service which diagnoses and treats ill health to one that predicts and prevents it. 'Genomics presents us with the opportunity to leapfrog disease, so we're in front of it rather than reacting to it.' Mr Streeting has previously spoken about his desire to make the NHS more preventative, reducing rates of serious illness and saving money in the process. The plan is also likely to see a greater role for artificial intelligence and other technologies to predict illness and allow treatment or medication to be offered much earlier. Mr Streeting has previously spoken about his desire to make the NHS more preventative, reducing rates of serious illness and saving money in the process. The plan is also likely to see a greater role for artificial intelligence and other technologies to predict illness and allow treatment or medication to be offered much earlier. He added: 'With the power of this new technology, patients will be able to receive personalised healthcare to prevent ill health before symptoms begin, reducing the pressure on NHS services and helping people live longer, healthier lives.' Along with a greater focus on prevention, the Government's 10-year plan is expected to include Mr Streeting's two other 'shifts' in the NHS. That will see a shift away from hospitals towards more community-focused care, and from analogue to digital services. It follows Chancellor Rachel Reeves' announcement that the Government would increase NHS funding by £29 billion per year in real terms over the next three years as it tries to cut waiting lists in line with its election promises.
